Related Experiment Video
Updated: May 5, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma
Michael A Postow1, Jianda Yuan, Shigehisa Kitano
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Abstract:
Therapeutic strategies that block Cytotoxic T lymphocyte antigen-4 (CTLA-4) enhance antitumor immunity and prolong the lives of patients with metastatic melanoma. However, only a subset of patients benefit, and responses are often delayed due to heterogeneous response kinetics. Ongoing monitoring of the immunologic effects of therapy and correlating these immunologic changes with patient outcomes continue to be important goals to better identify possible mechanisms of clinical activity of these agents. This chapter introduces the major areas of investigation in monitoring patients treated with CTLA-4 blockade and provides specific details of our experience performing selected assays.
Insights
Blocking Cytotoxic T lymphocyte antigen-4 (CTLA-4) improves anti-tumor immunity in melanoma patients. Monitoring immune changes helps understand treatment effectiveness and patient outcomes for these immunotherapies.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade is a therapeutic strategy that enhances antitumor immunity.
- While effective in prolonging lives of metastatic melanoma patients, only a subset benefits, and responses can be delayed.
- Understanding the immunologic effects and correlating them with patient outcomes is crucial for optimizing CTLA-4 blockade therapy.
Purpose of the Study:
- To introduce major areas of investigation for monitoring patients treated with CTLA-4 blockade.
- To provide specific details of experience performing selected assays for monitoring CTLA-4 blockade effects.
- To correlate immunologic changes with patient outcomes in metastatic melanoma.
Main Methods:
- Review of major investigation areas in monitoring CTLA-4 blockade.
- Detailed description of selected immunological assays performed.
- Correlation analysis between immunologic monitoring data and clinical outcomes.
Main Results:
- Identification of key areas for monitoring immunologic effects of CTLA-4 blockade.
- Demonstration of practical application of selected monitoring assays.
- Insights into the relationship between immune response kinetics and clinical benefit.
Conclusions:
- Ongoing monitoring of immunologic effects is vital for understanding CTLA-4 blockade mechanisms.
- Selected assays provide valuable data for correlating immune changes with patient outcomes.
- Further research correlating immune monitoring with clinical response can optimize melanoma treatment.
More Related Videos
09:57Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
Published on: January 29, 2019
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
